openPR Logo
Press release

3D Printed Drugs Market Impact due to COVID 19 Along with Analysis of The Current Situation and New Emerging Trends

05-07-2020 12:18 PM CET | Health & Medicine

Press release from: Allied Market Research

3D Printed Drugs Market

3D Printed Drugs Market

3D Printed Drugs Market is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4508

3D printed drugs are medications created by 3D printing technology that are used to treat patients suffering from dysphagia. 3D printed drugs have porous structures that can disintegrate rapidly inside the mouth itself. Aprecia Pharmaceuticals Companys SPRITAM levetiracetam is the first 3D printed drug, which has been approved by the U.S. Food and Drug Administration (FDA) in August 2015.

Constant technological developments in 3D printing technique, rise in incidence of epilepsy cases, and increase in awareness about the 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

The global 3D printed drugs market is analyzed based on forecast scenario such as low growth scenario, moderate growth scenario, and rapid growth scenario.

According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market.

However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4508
Key Findings of 3D Printed Drugs Market:
o In North America, the U.S. is anticipated to dominate the market in 2020, whereas rest of North America is projected to grow at the highest CAGR during the forecast period.
o Germany was the major shareholder in the European 3D printed drugs market in 2016.
o Asia-Pacific is expected to register the highest growth rate in future.
o Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market.

The key players profiled in this report include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 3D Printed Drugs Market Impact due to COVID 19 Along with Analysis of The Current Situation and New Emerging Trends here

News-ID: 2037478 • Views: 165

More Releases from Allied Market Research

Smart Beacon Market Expected to Reach $103.94 Billion By 2030 at 37.7% CAGR | Gr …
Rise in modern-day communication technologies, surge in investments in proximity marketing, and increase in adoption of smart devices are the factors that drive the global smart beacon market growth. As per the report published by Allied Market Research, the global smart beacon market generated $3.28 billion in 2020, and is estimated to reach $103.94 billion by 2030, witnessing a CAGR of 37.7% from 2021 to 2030. The report provides a
Fantasy Sports Market in Asia-Pacific & Canada is Expected to Reach $3,739.8 Mil …
According to a new report published by Allied Market Research, titled, “Asia-Pacific & Canada Fantasy Sports Market by Sports Type, Platform, and Demographic: Regional Opportunity Analysis and Industry Forecast, 2021–2027,” Asia-Pacific & Canada fantasy sports market size was valued at $2,021.9 million in 2019, and is projected to reach $3,739.8 million by 2027, growing at a CAGR of 10.7% from 2021 to 2027. Fantasy sport is played using internet where participants
Hammock Market Size Is Projected Reach $639.8 Million By 2030, Registering At A …
Surge in hiking and adventure tourism, rise in demand from residential segment, and expansion of hospitality industry drive the growth of the global hammock market. North America contributed to the highest share in terms of revenue in 2020. The outbreak of the COVID-19 pandemic has resulted in transition of consumers toward online sales channels to purchase campaigning gear products including hammocks. According to the report published by Allied Market Research, the
Cotton Personal-Care Product Market 2021: Top Factors That Are Leading The Deman …
A lead analyst at AMR highlighted the market across Europe region is expected to dominate in terms of revenues throughout the forecast period. Allied Market Research published a research report on the Cotton personal-care product market. The findings of the report states that the global market for Cotton personal-care product is expected to reach $19.15 billion by 2028, manifesting a CAGR of 4.6% from 2020 to 2028. The report provides valuable

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning